Xujie Zhuang
State Key Laboratory Of Natural Medicines And Jiangsu Provincial Key Laboratory Of Targetome And Innovative Drugs Medicines
Nanjing, 211198, China
Nanjing, 211198, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer.
Journal: Bioorganic chemistry
Published: May 28, 2026
Preclinical Efficacy of TSL2109 in Prostate Cancer Treatment and Overcoming Enzalutamide Resistance.
Preclinical Efficacy of TSL2109 in Prostate Cancer Treatment and Overcoming Enzalutamide Resistance.
Journal: Journal of medicinal chemistry
Published: December 09, 2025
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer.
Journal: European journal of medicinal chemistry
Published: January 17, 2025
Comprehensive analysis of molecular characteristics between primary and breast-derived metastatic ovarian cancer.
Journal: Translational cancer research
Published: August 17, 2024
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment.
Journal: Chinese journal of natural medicines
Published: February 26, 2024
Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer.
Journal: Journal of medicinal chemistry
Published: November 30, 2023
Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: May 04, 2023
Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer.
Journal: Journal of medicinal chemistry
Published: February 17, 2023
Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer.
Journal: iScience
Published: September 28, 2022
A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer.
Journal: Journal of oncology
Published: July 23, 2022
Integrative analysis identifies three molecular subsets in ovarian cancer.
Journal: Clinical and translational medicine
Published: May 18, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026